Pharmacotherapy of aphasia: Myth or reality?

Brain and Language

Volumn 102, Issue 1, 2007, Pages 114-125

  de Boissezon, Xavier ^a,b   Peran, Patrice ^a,c   de Boysson, Chloé ^a   Démonet, Jean François ^a  

^a CHU PURPAN   (France)

^b CHU RANGUEIL   (France)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Aphasia; Drug therapy; Pharmacological treatment; Pharmacotherapy; Stroke

Indexed keywords

AMPHETAMINE; ANIRACETAM; BIFEMELANE; BROMOCRIPTINE; CHLORDIAZEPOXIDE; CHOLINESTERASE INHIBITOR; DEXAMPHETAMINE; DONEPEZIL; FLUOXETINE; FLUVOXAMINE; METHYLPHENIDATE; MOCLOBEMIDE; NILVADIPINE; PAROXETINE; PIRACETAM; PLACEBO; ZOLPIDEM;

APHASIA; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFICACY; HEMODYNAMICS; HUMAN; NEUROMODULATION; PRACTICE GUIDELINE; SPEECH THERAPY;

AMPHETAMINE; APHASIA; BROMOCRIPTINE; CEREBROVASCULAR ACCIDENT; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; DOPAMINE AGENTS; FLUOXETINE; GABA AGONISTS; HUMANS; INDANS; NEUROPROTECTIVE AGENTS; PAROXETINE; PHYSOSTIGMINE; PIPERIDINES; PIRACETAM; PYRIDINES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 34249311252     PISSN: 0093934X     EISSN: 10902155     Source Type: Journal    
DOI: 10.1016/j.bandl.2006.07.004     Document Type: Article

References (52)

1. Albert M.L., Bachman D.L., Morgan A., and Helm-Estabrooks N. Pharmacotherapy for aphasia. Neurology 38 (1988) 877-879
2. Baz D.V., Bofill J.S., and Nogueira J.A. Irinotecan-induced dysarthria. J. Natl. Cancer Inst. 93 (2001) 1419-1420
3. Benson D. Presentation 10. In: Benton A. (Ed). Behavioural change in cerebrovascular disease (1970), Harper and Row, New York 77
4. Berthier M.L., Hinojosa J., Martin Mdel C., and Fernandez I. Open-label study of donepezil in chronic poststroke aphasia. Neurology 60 (2003) 1218-1219
5. Bragoni M., Altieri M., Di Piero V., Padovani A., Mostardini C., and Lenzi G.L. Bromocriptine and speech therapy in non-fluent chronic aphasia after stroke. Neurol. Sci. 21 (2000) 19-22
6. Clauss R.P., Guldenpfennig W.M., Nel H.W., Sathekge M.M., and Venkannagari R.R. Extraordinary arousal from semi-comatose state on zolpidem. A case report. S. Afr. Med. J. 90 (2000) 68-72
7. Cohen L., Chaaban B., and Habert M.O. Transient improvement of aphasia with zolpidem. N. Engl. J. Med. 350 (2004) 949-950
8. Darley F.L., Keith R.L., and Sasanuma S. The effect of alerting and tranquilizing drugs upon the performance of aphasic patients. Clin. Aphasiol. 7 (1977) 91-96
9. De Marco S., Squilloni E., Vigna L., Bertagnolio M.F., and Sternberg C.N. Irinotecan chemotherapy associated with transient dysarthria and aphasia. Ann. Oncol. 15 (2004) 1147-1148
10. Enderby P., Broeckx J., Hospers W., Schildermans F., and Deberdt W. Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebo-controlled study. Clin. Neuropharmacol. 17 (1994) 320-331
11. Feeney D.M., Gonzalez A., and Law W.A. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 217 (1982) 855-857
12. Feeney D.M., and Hovda D.A. Reinstatement of binocular depth perception by amphetamine and visual experience after visual cortex ablation. Brain Res. 342 (1985) 352-356
13. Feeney D.M., and Sutton R.L. Pharmacotherapy for recovery of function after brain injury. Crit. Rev. Neurobiol. 3 (1987) 135-197
14. Gerdelat-Mas A., Loubinoux I., Tombari D., Rascol O., Chollet F., and Simonetta-Moreau M. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. Neuroimage 27 (2005) 314-322
15. Gold M., VanDam D., and Silliman E.R. An open-label trial of bromocriptine in nonfluent aphasia: a qualitative analysis of word storage and retrieval. Brain Lang. 74 (2000) 141-156
16. Goldstein L.B., and Davis J.N. Influence of lesion size and location on amphetamine-facilitated recovery of beam-walking in rats. Behav. Neurosci. 104 (1990) 320-327
17. Greener J., Enderby P., and Whurr R. Speech and language therapy for aphasia following stroke. Cochrane Database Syst. Rev. (2000) CD000425
18. Gupta S.R., and Mlcoch A.G. Bromocriptine treatment of nonfluent aphasia. Arch. Phys. Med. Rehabil. 73 (1992) 373-376
19. Gupta S.R., Mlcoch A.G., Scolaro C., and Moritz T. Bromocriptine treatment of nonfluent aphasia. Neurology 45 (1995) 2170-2173
20. Hillis A.E., Barker P.B., Wityk R.J., Aldrich E.M., Restrepo L., Breese E.L., and Work M. Variability in subcortical aphasia is due to variable sites of cortical hypoperfusion. Brain Lang. 89 (2004) 524-530
21. Hillis A.E., Kane A., Tuffiash E., Ulatowski J.A., Barker P.B., Beauchamp N.J., and Wityk R.J. Reperfusion of specific brain regions by raising blood pressure restores selective language functions in subacute stroke. Brain Lang. 79 (2001) 495-510
22. Holland A.L., Fromm D.S., DeRuyter F., and Stein M. Treatment efficacy: aphasia. J. Speech Hear Res. 39 (1996) S27-S36
23. Huber W. The role of piracetam in the treatment of acute and chronic aphasia. Pharmacopsychiatry 32 Suppl. 1 (1999) 38-43
24. Huber W., Willmes K., Poeck K., Van Vleymen B., and Deberdt W. Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study. Arch. Phys. Med. Rehabil. 78 (1997) 245-250
25. Jorgensen H.S., Nakayama H., Raaschou H.O., Vive-Larsen J., Stoier M., and Olsen T.S. Outcome and time course of recovery in stroke. Part II: Time course of recovery. The Copenhagen stroke study. Arch. Phys. Med. Rehabil. 76 (1995) 406-412
26. Joseph P.A., de Seze M., Mazaux J.M., and Barat M. Evaluation de la rééducation de l'aphasie: revue de la littérature. In: Mazaux J.M., Brun V., and Pélissier J. (Eds). Aphasie 2000 (2000), Masson, Paris 172-177
27. Kertesz A., Harlock W., and Coates R. Computer tomographic localization, lesion size, and prognosis in aphasia and nonverbal impairment. Brain Lang. 8 (1979) 34-50
28. Kessler J., Thiel A., Karbe H., and Heiss W.D. Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke 31 (2000) 2112-2116
29. Kozlowski D.A., James D.C., and Schallert T. Use-dependent exaggeration of neuronal injury after unilateral sensorimotor cortex lesions. J. Neurosci. 16 (1996) 4776-4786
30. Laska A.C., von Arbin M., Kahan T., Hellblom A., and Murray V. Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: a randomised, double-blind, placebo-controlled study. Cerebrovasc. Dis. 19 (2005) 125-132
31. Loubinoux I., Tombari D., Pariente J., Gerdelat-Mas A., Franceries X., Cassol E., et al. Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. Neuroimage 27 (2005) 299-313
32. Luria A., Naydyn V.L., Tsvetkova L.S., and Vinarskaya E.N. Restoration of higher cortical function following local brain damage. In: Vinken P.J., and Bruyn G.W. (Eds). Handbook of clinical neurology (1969), North-Holland Publishing Company, Amsterdam 368-433
33. Naeser M.A., Martin P.I., Nicholas M., Baker E.H., Seekins H., Kobayashi M., et al. Improved picture naming in chronic aphasia after TMS to part of right Broca's area: an open-protocol study. Brain Lang. 93 (2005) 95-105
34. Orgogozo J.M. Piracetam in the treatment of acute stroke. Pharmacopsychiatry 32 Suppl. 1 (1999) 25-32
35. Ozeren A., Sarica Y., Mavi H., and Demirkiran M. Bromocriptine is ineffective in the treatment of chronic nonfluent aphasia. Acta. Neurol. Belg. 95 (1995) 235-238
36. Pariente J., Loubinoux I., Carel C., Albucher J.F., Leger A., Manelfe C., et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann. Neurol. 50 (2001) 718-729
37. Peran P., Cassol E., Tombari D., Loubinoux I., Demonet J.F., and Cardebat D. Paroxetine-induced modulation of cortical activity in language processing. Neuroimage 22 (2004) e138
38. Porch, B., Wyckes, J., & Feeney, D.M. (1985). Haloperidol, Thiazides and some antihypertensives slow recovery from aphasia. Proceedings of the Annual Meeting of the Society for Neuroscience, 52.
39. Raymer A.M., Bandy D., Adair J.C., Schwartz R.L., Williamson D.J., Gonzalez Rothi L.J., et al. Effects of bromocriptine in a patient with crossed nonfluent aphasia: a case report. Arch. Phys. Med. Rehabil. 82 (2001) 139-144
40. Reed D.A., Johnson N.A., Thompson C., Weintraub S., and Mesulam M.M. A clinical trial of bromocriptine for treatment of primary progressive aphasia. Ann. Neurol. 56 (2004) 750
41. Sabe L., Leiguarda R., and Starkstein S.E. An open-label trial of bromocriptine in nonfluent aphasia. Neurology 42 (1992) 1637-1638
42. Sabe L., Salvarezza F., Garcia Cuerva A., Leiguarda R., and Starkstein S. A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia. Neurology 45 (1995) 2272-2274
43. Sevilla Garcia I., Rueda A., and Alba E. Irinotecan-induced central nervous system toxicity: a case report. J. Natl. Cancer Inst. 91 (1999) 647
44. Small S.L. Pharmacotherapy of aphasia. A critical review. Stroke 25 (1994) 1282-1289
45. Szelies B., Mielke R., Kessler J., and Heiss W.D. Restitution of alpha-topography by piracetam in post-stroke aphasia. Int. J. Clin. Pharmacol. Ther. 39 (2001) 152-157
46. Tanaka Y., Albert M.L., Aketa S., Hujita K., Noda E., Takashima M., et al. Serotoniergic therapy for fluent aphasia. Neurology 62 (2004) A166
47. Tanaka Y., Albert M.L., Yokoyama E., Nonaka C., Aketa S., Hujita K., et al. Cholinergic therapy of anomia in fluent aphasia. Ann. Neurol. (2001) S61
48. Tanaka Y., Miyazaki M., and Albert M.L. Effects of increased cholinergic activity on naming in aphasia. Lancet 350 (1997) 116-117
49. Vernon M.W., and Sorkin E.M. Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1 (1991) 17-35
50. Walker-Batson D., Curtis S., Natarajan R., Ford J., Dronkers N., Salmeron E., et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke 32 (2001) 2093-2098
51. Walker-Batson D., Devous M., Curtis S., Unwin D.H., and Greenlee R. Response to amphetamine to facilitate recovery from aphasia subsequent to stroke. Clin. Aphasiol. 21 (1991) 137-143
52. Walker-Batson D., Smith P., Curtis S., Unwin H., and Greenlee R. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke 26 (1995) 2254-2259